Hemodynamic Determinants of Dyspnea Improvement in Acute Decompensated Heart Failure

被引:30
作者
Solomonica, Amir [1 ]
Burger, Andrew J. [2 ,3 ,4 ]
Aronson, Doron [1 ]
机构
[1] Rambam Med Ctr, Dept Cardiol, IL-31096 Haifa, Israel
[2] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel
[3] Technion Israel Inst Technol, Res Inst, Haifa, Israel
[4] Univ Cincinnati, Div Cardiovasc Dis, Cincinnati, OH USA
关键词
acute heart failure; dyspnea; pulmonary capillary wedge pressure; pulmonary hypertension; CLINICAL-TRIALS; PULMONARY-HYPERTENSION; OUTCOMES; REGISTRY; MECHANISMS; MANAGEMENT; NESIRITIDE; THERAPIES; TOLVAPTAN; MORTALITY;
D O I
10.1161/CIRCHEARTFAILURE.112.970335
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Dyspnea relief constitutes a major treatment goal and a key measure of treatment efficacy in decompensated heart failure. However, there are no data with regard to the relationship between hemodynamic measurements during treatment and dyspnea improvement. Methods and Results-We studied 233 patients assigned to right heart catheterization in the Vasodilation in the Management of Acute Congestive Heart Failure trial. Dyspnea (assessed using a 7-point Likert scale) and hemodynamic parameters were measured simultaneously at 15 and 30 minutes and 1, 2, 3, 6, and 24 hours. Dyspnea relief was defined as moderate or marked improvement. There was a time-dependent association between the reductions in pulmonary capillary wedge pressure (PCWP; 25.4, 24.6, 24.0, 23.5, 23.4, 21.5, and 19.9 mm Hg) and the percentage of patients achieving dyspnea relief (17.7%, 24.6%, 32.2%, 36.2%, 37.8%, 47.4%, and 66.1%, in the respective time points). Multivariable logistic generalized estimating equations modeling demonstrated that reductions of both PCWP and mean pulmonary artery pressure were independently associated with dyspnea relief. Compared with the highest PCWP quartile, the adjusted odds ratios for dyspnea relief were 0.92 (95% confidence interval [CI], 0.67-1.29), 1.07 (95% CI, 0.75-1.55), and 1.80 (95% CI, 1.22-2.65) in the third, second, and first PCWP quartiles, respectively (P-trend=0.003). Compared with the highest mean pulmonary artery pressure quartile, the adjusted odds ratios for dyspnea relief were 2.0 (95% CI, 1.41-2.82), 2.23 (95% CI, 1.52-3.27), and 2.98 (95% CI, 1.91-4.66) in the third, second, and first mean pulmonary artery pressure quartiles, respectively (P-trend<0.0001). Conclusions-A clinically significant improvement in dyspnea is associated with a reduction in both PCWP and mean pulmonary artery pressure.
引用
收藏
页码:53 / +
页数:11
相关论文
共 34 条
[1]   Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000, cases in the Acute Decompensated Heart Failure National Registry (ADHERE) [J].
Adams, KF ;
Fonarow, GC ;
Emerman, CL ;
LeJemtel, TH ;
Costanzo, MR ;
Abraham, WT ;
Berkowitz, RL ;
Galvao, M ;
Horton, DP .
AMERICAN HEART JOURNAL, 2005, 149 (02) :209-216
[2]   Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF) [J].
Allen, Larry A. ;
Metra, Marco ;
Milo-Cotter, Olga ;
Filippatos, Gerasimos ;
Reisin, Leonardo H. ;
Bensimhon, Daniel R. ;
Gronda, Edoardo G. ;
Colombo, Paolo ;
Felker, G. Michael ;
Cas, Livio Dei ;
Kremastinos, Dimitrios T. ;
O'Connor, Christopher M. ;
Cotter, Gadi ;
Davison, Beth A. ;
Dittrich, Howard C. ;
Velazquez, Eric J. .
JOURNAL OF CARDIAC FAILURE, 2008, 14 (09) :777-784
[3]   End Points for Clinical Trials in Acute Heart Failure Syndromes [J].
Allen, Larry A. ;
Hernandez, Adrian F. ;
O'Connor, Christopher M. ;
Felker, G. Michael .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (24) :2248-2258
[4]   Novel therapies in acute and chronic heart failure [J].
Aronson, Doron ;
Krum, Henry .
PHARMACOLOGY & THERAPEUTICS, 2012, 135 (01) :1-17
[5]   Relationship Between Reactive Pulmonary Hypertension and Mortality in Patients With Acute Decompensated Heart Failure [J].
Aronson, Doron ;
Eitan, Amnon ;
Dragu, Robert ;
Burger, Andrew J. .
CIRCULATION-HEART FAILURE, 2011, 4 (05) :644-650
[6]   Pulmonary hypertension and exercise intolerance in patients with heart failure [J].
Butler, J ;
Chomsky, DB ;
Wilson, JR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (06) :1802-1806
[7]   Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. [J].
Colucci, WS ;
Elkayam, U ;
Horton, DP ;
Abraham, WT ;
Bourge, RC ;
Johnson, AD ;
Wagoner, LE ;
Givertz, MM ;
Liang, CS ;
Neibaur, M ;
Haught, WH .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (04) :246-253
[8]   Fluid overload in acute heart failure - Re-distribution and other mechanisms beyond fluid accumulation [J].
Cotter, Gad ;
Metra, Marco ;
Milo-Cotter, Olga ;
Dittrich, Howard C. ;
Gheorghiade, Mihai .
EUROPEAN JOURNAL OF HEART FAILURE, 2008, 10 (02) :165-169
[9]   Sympathetically Mediated Changes in Capacitance Redistribution of the Venous Reservoir as a Cause of Decompensation [J].
Fallick, Catherine ;
Sobotka, Paul A. ;
Dunlap, Mark E. .
CIRCULATION-HEART FAILURE, 2011, 4 (05) :669-675
[10]   The pulmonary manifestations of left heart failure [J].
Gehlbach, BK ;
Geppert, E .
CHEST, 2004, 125 (02) :669-682